Insider Transactions in Q1 2022 at Vigil Neuroscience, Inc. (VIGL)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2022
|
Clay Thorp Director |
BUY
Open market or private purchase
|
Direct |
3,000
+50.0%
|
$21,000
$7.2 P/Share
|
|
Jan 11
2022
|
Cormorant Asset Management, LP |
BUY
Conversion of derivative security
|
Indirect |
616,786
+50.0%
|
-
|
|
Jan 11
2022
|
Alexandria Venture Investments, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
192,973
+50.0%
|
-
|
|
Jan 11
2022
|
Northpond Ventures Gp, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
355,000
+20.43%
|
$4,970,000
$14.0 P/Share
|
|
Jan 11
2022
|
Northpond Ventures Gp, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,859,498
+50.0%
|
-
|
|
Jan 11
2022
|
Stefan Vitorovic |
BUY
Open market or private purchase
|
Indirect |
1,675,000
+25.03%
|
$23,450,000
$14.0 P/Share
|
|
Jan 11
2022
|
Stefan Vitorovic |
BUY
Conversion of derivative security
|
Indirect |
3,340,929
+50.0%
|
-
|
|
Jan 11
2022
|
Bruce Booth |
BUY
Open market or private purchase
|
Indirect |
535,000
+10.01%
|
$7,490,000
$14.0 P/Share
|
|
Jan 11
2022
|
Bruce Booth |
BUY
Conversion of derivative security
|
Indirect |
3,859,498
+44.93%
|
-
|
|
Jan 11
2022
|
Atlas Venture Fund Xii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
535,000
+10.01%
|
$7,490,000
$14.0 P/Share
|
|
Jan 11
2022
|
Atlas Venture Fund Xii, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,859,498
+44.93%
|
-
|
|
Jan 11
2022
|
Vida Ventures Gp Iii, L.L.C. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,675,000
+25.03%
|
$23,450,000
$14.0 P/Share
|
|
Jan 11
2022
|
Vida Ventures Gp Iii, L.L.C. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,340,929
+50.0%
|
-
|
|
Jan 11
2022
|
Clay Thorp Director |
BUY
Open market or private purchase
|
Indirect |
265,000
+14.85%
|
$3,710,000
$14.0 P/Share
|
|
Jan 11
2022
|
Clay Thorp Director |
BUY
Conversion of derivative security
|
Indirect |
1,254,335
+50.0%
|
-
|
|
Jan 11
2022
|
Amgen Inc > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
3,206,281
+50.0%
|
-
|